TFF1 anticorps (AA 57-84)

N° du produit ABIN3025059

L’anticorps Souris Monoclonal anti-TFF1 a été validé pour IF, FACS et IHC (p). Il convient pour détecter TFF1 dans des échantillons de Humain et Cynomolgus.

Aperçu rapide pour TFF1 anticorps (AA 57-84) (ABIN3025059)

Antigène: TFF1 (Trefoil Factor 1 (TFF1))

Reactivité: Humain, Cynomolgus

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp TFF1 est non-conjugé

Application: Immunofluorescence (IF), Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: SPM313

Détail du produit anti-TFF1 anticorps

Épitope: AA 57-84

Attributs du produit: It recognizes a polypeptide of 6.5 kDa, identified as pS2 estrogen-regulated protein. Its epitope is localized between aa57-84 of human pS2 protein. pS2 is a trefoil peptide. Trefoil peptides are protease resistant molecules secreted throughout the gut that play a role in mucosal healing. These peptides contain three intra-chain disulfide bonds, forming the trefoil motif, or P-domain. pS2 is known to form dimers and this dimerization is thought to play a role in its protective and healing properties. About 60 % of breast carcinomas are positive for pS2. Staining is cytoplasmic, often with localization to the Golgi apparatus. pS2 is shown to be localized in normal stomach mucosa, gastric fluid, goblet cells in the colon and small intestine, and in ulcerations of the gastrointestinal tract. Several studies have shown that pS2 is primarily expressed in estrogen receptor-positive breast tumors and it may define a subset of estrogen-dependent tumors that displays an increased likelihood of response to endocrine therapy.

Purification: Protein G affinity chromatography

Immunogène: Amino acids CFDDTVRGVPWCFYPNTIDVPPEEECEF (aa57-84) from the human protein were used as the immunogen for the Estrogen Inducible Protein pS2 antibody.

Isotype: IgG1 kappa

Information d'application

Indications d'application: Optimal dilution of the Estrogen Inducible Protein pS2 antibody should be determined by the researcher.

1. Staining of formalin-fixed tissues requires boiling tissue sections in 10  mM Citrate buffer,  pH 6.0, for 10-20 min followed by cooling at RT for 20 min.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. Flow Cytometry: 0.5-1 μg/million cells in 0.1ml,Immunofluorescence: 0.5-1 μg/mL,Immunohistochemistry (FFPE): 0.5-1 μg/mL for 30 min at RT (1),Prediluted format: incubate for 30 min at RT (2)

Restrictions: For Research Use only

Stockage

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Agent conservateur: Azide free

Stock: 4 °C,-20 °C

Stockage commentaire: Store the Estrogen Inducible Protein pS2 antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).

Détails sur TFF1

Antigène: TFF1 (Trefoil Factor 1 (TFF1))

Autre désignation: Estrogen Inducible Protein pS2

Sujet: It recognizes a polypeptide of 6.5  kDa, identified as pS2 estrogen-regulated protein. Its epitope is localized between aa57-84 of human pS2 protein. pS2 is a trefoil peptide. Trefoil peptides are protease resistant molecules secreted throughout the gut that play a role in mucosal healing. These peptides contain three intra-chain disulfide bonds, forming the trefoil motif, or P-domain. pS2 is known to form dimers and this dimerization is thought to play a role in its protective and healing properties. About 60 % of breast carcinomas are positive for pS2. Staining is cytoplasmic, often with localization to the Golgi apparatus. pS2 is shown to be localized in normal stomach mucosa, gastric fluid, goblet cells in the colon and small intestine, and in ulcerations of the gastrointestinal tract. Several studies have shown that pS2 is primarily expressed in estrogen receptor-positive breast tumors and it may define a subset of estrogen-dependent tumors that displays an increased likelihood of response to endocrine therapy.

Pathways: EGFR Signaling Pathway